Last reviewed · How we verify
LEO 90100 foam
LEO 90100 foam is a topical corticosteroid formulation designed for enhanced skin penetration and anti-inflammatory effects in dermatological conditions.
LEO 90100 foam is a topical corticosteroid formulation designed for enhanced skin penetration and anti-inflammatory effects in dermatological conditions. Used for Inflammatory skin conditions (psoriasis, atopic dermatitis, or other dermatitis).
At a glance
| Generic name | LEO 90100 foam |
|---|---|
| Also known as | Enstilar® Foam |
| Sponsor | LEO Pharma |
| Drug class | Topical corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
LEO 90100 is a potent topical corticosteroid delivered in a foam vehicle that improves drug delivery to affected skin areas. The foam formulation enhances spreadability and penetration while reducing systemic absorption compared to traditional formulations. It works by suppressing inflammatory responses and immune activity in the skin.
Approved indications
- Inflammatory skin conditions (psoriasis, atopic dermatitis, or other dermatitis)
Common side effects
- Application site irritation
- Skin atrophy
- Folliculitis
Key clinical trials
- A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (PHASE3)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis (PHASE2)
- Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris (PHASE2)
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |